<< Back

Press Release

September 7, 2017 at 6:16 PM EDT

Innoviva to Participate in Morgan Stanley's Global Healthcare Unplugged Conference on September 12

BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present in a fireside chat format discussion at the Morgan Stanley 15th Annual Global Healthcare Conference at the Grand Hyatt Hotel in New York, NY, on Tuesday, September 12, 2017, from 1:30PM to 2:00PM ET.

The presentation will be webcast live and may be accessed via this link: https://cc.talkpoint.com/morg007/091117a_as/?entity=143_8HX8DXD.

About Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc., including the closed triple combination therapy for Chronic Obstructive Pulmonary Disease (COPD). For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Innoviva, Inc.
Eric d'Esparbes
Senior Vice President and Chief Financial Officer
650-238-9640
investor.relations@inva.com

Source: Innoviva, Inc.

News Provided by Acquire Media

s

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.